دورية أكاديمية
أعرض في EDS

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.

التفاصيل البيبلوغرافية
العنوان: Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.
المؤلفون: Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Sharman JP; Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR., Ghia P; Division of Experimental Oncology, Università Vita-Salute San Raffaele, Milan, Italy.; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Eyre TA; Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Jurczak W; Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland., Siddiqi T; City of Hope Comprehensive Cancer Center, Duarte, CA., Miranda P; AstraZeneca, Gaithersburg, MD., Shahkarami M; AstraZeneca, South San Francisco, CA., Butturini A; AstraZeneca, South San Francisco, CA., Emeribe U; AstraZeneca, Gaithersburg, MD., Byrd JC; Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.
المصدر: Blood advances [Blood Adv] 2024 Jul 09; Vol. 8 (13), pp. 3345-3359.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Society of Hematology, [2016]-
مواضيع طبية MeSH: Pyrazines*/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell*/mortality , Benzamides*/therapeutic use, Humans ; Male ; Aged ; Female ; Middle Aged ; Aged, 80 and over ; Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Recurrence ; Clinical Trials as Topic ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/administration & dosage ; Treatment Outcome
مستخلص: Abstract: Before targeted therapies, patients with higher-risk chronic lymphocytic leukemia (CLL), defined as del(17p) and/or TP53 mutation (TP53m), unmutated immunoglobulin heavy chain variable region genes (uIGHV), or complex karyotype (CK), had poorer prognosis with chemoimmunotherapy. Bruton tyrosine kinase inhibitors (BTKis) have demonstrated benefit in higher-risk patient populations with CLL in individual trials. To better understand the impact of the second-generation BTKi acalabrutinib, we pooled data from 5 prospective clinical studies of acalabrutinib as monotherapy or in combination with obinutuzumab (ACE-CL-001, ACE-CL-003, ELEVATE-TN, ELEVATE-RR, and ASCEND) in patients with higher-risk CLL in treatment-naive (TN) or relapsed/refractory (R/R) cohorts. A total of 808 patients were included (TN cohort, n = 320; R/R cohort, n = 488). Median follow-up was 59.1 months (TN cohort) and 44.3 months (R/R cohort); 51.3% and 26.8% of patients in the TN and R/R cohorts, respectively, remained on treatment at last follow-up. In the del(17p)/TP53m, uIGHV, and CK subgroups in the TN cohort, median progression-free survival (PFS) and median overall survival (OS) were not reached (NR). In the del(17p)/TP53m, uIGHV, and CK subgroups in the R/R cohort, median PFS was 38.6 months, 46.9 months, and 38.6 months, respectively, and median OS was 60.6 months, NR, and NR, respectively. The safety profile of acalabrutinib-based therapy in this population was consistent with the known safety profile of acalabrutinib in a broad CLL population. Our analysis demonstrates long-term benefit of acalabrutinib-based regimens in patients with higher-risk CLL, regardless of line of therapy.
(© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
References: Hemasphere. 2022 Nov 14;6(12):e801. (PMID: 36398134)
Blood. 2022 Aug 25;140(8):839-850. (PMID: 35605176)
Lancet. 2020 Apr 18;395(10232):1278-1291. (PMID: 32305093)
Ann Oncol. 2021 Jan;32(1):23-33. (PMID: 33091559)
Blood. 2008 Jun 15;111(12):5446-56. (PMID: 18216293)
N Engl J Med. 2019 Jun 06;380(23):2225-2236. (PMID: 31166681)
N Engl J Med. 2023 Jan 26;388(4):319-332. (PMID: 36511784)
J Clin Oncol. 2020 Dec 1;38(34):4042-4054. (PMID: 32986498)
Haematologica. 2020 Jan 23;106(1):87-97. (PMID: 31974198)
Blood. 2021 Jun 17;137(24):3327-3338. (PMID: 33786588)
Leukemia. 2022 Apr;36(4):1171-1175. (PMID: 34974526)
Cancer Discov. 2020 Mar;10(3):394-405. (PMID: 31915195)
Blood. 2020 Apr 9;135(15):1204-1213. (PMID: 31876911)
J Pharmacol Exp Ther. 2023 Jan;384(1):173-186. (PMID: 36310034)
Blood. 2018 Jun 21;131(25):2745-2760. (PMID: 29540348)
Nat Commun. 2023 Apr 18;14(1):2147. (PMID: 37072421)
J Clin Oncol. 2020 Sep 1;38(25):2849-2861. (PMID: 32459600)
Lancet Oncol. 2022 Aug;23(8):1031-1043. (PMID: 35810754)
J Clin Oncol. 2021 Nov 1;39(31):3441-3452. (PMID: 34310172)
Br J Haematol. 2022 Feb;196(4):947-953. (PMID: 34865212)
المشرفين على المادة: I42748ELQW (acalabrutinib)
0 (Pyrazines)
0 (Benzamides)
0 (Antibodies, Monoclonal, Humanized)
O43472U9X8 (obinutuzumab)
تواريخ الأحداث: Date Created: 20240419 Date Completed: 20240626 Latest Revision: 20240720
رمز التحديث: 20240720
مُعرف محوري في PubMed: PMC11255369
DOI: 10.1182/bloodadvances.2023011307
PMID: 38640349
قاعدة البيانات: MEDLINE
الوصف
تدمد:2473-9537
DOI:10.1182/bloodadvances.2023011307